1 Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 INSERM U589, Institut Louis Bugnard, 31403 Toulouse, France
3 Orthopaedic Research Laboratories, University of Washington, Seattle, WA 98195, USA
4 Department of Pediatrics, UCLA School of Medicine, CA 90095, USA
* Author for correspondence (e-mail: william.wilcox{at}cshs.org)
Accepted 8 August 2005
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Fibroblast growth factor, C-natriuretic peptide, Mitogen-activated protein kinase, Growth arrest, Extracellular Matrix, Chondrocyte
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Natriuretic peptides comprise a family of three structurally related peptides: atrial natriuretic peptide, brain natriuretic peptide and C-natriuretic peptide (CNP) (Rosenzweig and Seidman, 1991). Unlike atrial and brain natriuretic peptides that act via the bloodstream (Mukoyama et al., 1991
), CNP acts locally in a variety of tissues (Koller et al., 1992). CNP has recently emerged as an important regulator of longitudinal bone growth. Genetic ablation of CNP or its signaling components results in severe skeletal dysplasias caused by reduced chondrocyte proliferation and differentiation (Chusho et al., 2001
; Miyazawa et al., 2002
; Tamura et al., 2004
). Loss-of-function mutations in the CNP cognate receptor, natriuretic peptide receptor (NPR)-B, causes an achondroplasia-like dwarfism in mice and acromesomelic dysplasia, type Maroteaux in humans (Tsuji and Kunieda, 2005
; Bartels et al., 2004
). In limb organ culture, CNP upregulates chondrocyte proliferation and cartilage matrix production (Yasoda et al., 1998
; Mericq et al., 2000
). However, the molecular basis of CNP action in cartilage remains unclear. Since the effects of CNP and FGF on endochondral bone growth appear to oppose each other, it is reasonable to propose a direct interaction of their signaling pathways. In fact, Yasoda et al. (Yasoda et al., 2004
) demonstrated that overexpression of CNP in the cartilage of a mouse model for achondroplasia partially rescues the disease phenotype by correcting the decreased extracellular matrix synthesis through inhibition of the Erk pathway.
Although the CNP-mediated reversal of FGF signaling in cartilage was demonstrated (Yasoda et al., 2004), the underlying mechanism remains unclear. In this study, we determined the molecular mechanism of FGF and CNP signaling interactions in a chondrocyte environment as well as the effects of such interactions on chondrocyte proliferation and extracellular matrix homeostasis.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Western immunoblotting (WB) and immunoprecipitation
Cells were lysed in immunoprecipitation buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, 25 mM NaF, 0.1 mM DTT, 1 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 1 mM PMSF, 8 mM ß-glycerolphosphate, 10 mM Na3VO4,1 µg/ml aprotinin). Lysates (20 µg) were resolved by SDS-PAGE and transferred onto a PVDF membrane. Blots were visualized by luminescence (Amersham, Piscataway, NJ). The following antibodies were used: actin, Erk2, MEK1, B-Raf, FRS2, NPR-B, NPR-C, MMP9, MMP13 (Santa Cruz Biotechnology, Santa Cruz, CA); Raf-1 (Transduction Laboratories, Lexington, KY); P-Raf-1S338, Erk1/2, P-Erk1/2T183/Y185, P-MEKS217/221, P-FRS2Y196 (Cell Signaling, Beverly, MA); Ras, 4G10 (Upstate Biotechnology, Lake Placid, NY); MMP10 (Lab Vision, Fremont, CA); MMP2 and MMP3 (Chermicon, Temecula, CA). For immunoprecipitation, 500 µg of total protein was incubated with 2 µg of Raf-1 (Transduction Laboratories), B-Raf or FRS2 antibody (Santa Cruz) for 2 hours at 4°C. Immunocomplexes were purified using A/G-agarose (Santa Cruz). Western blotting signal was quantitated by determining the integrated optical density (I.O.D.) of given band using the Scion Image software (Scion Corporation, Frederick, MA).
Signal transduction studies
Cells were serum starved for 12 hours before treatment with FGF2 for 30 minutes. When CNP, pCPT-cGMP, KT5823 (Calbiochem) or U0126 (Cell Signaling) were used, cells were pretreated for 30 minutes prior to FGF2 treatment. The phosphorylation status of Raf-1, Erk and MEK was detected by WB using the antibodies described above. Erk activity was determined using an Erk kinase assay kit (Cell Signaling). Briefly, Erk was immunoprecipitated from 200 µg of total protein and incubated with recombinant Elk-1 in the presence of ATP. Phosphorylation of Elk-1 at Ser383 was determined by WB. For the Raf kinase assay, Raf-1 or B-Raf immunocomplexes were washed with kinase buffer (25 mM Tris pH 7.5, 5 mM ß-glycerolphosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM MgCl2). The kinase reaction was performed for 30 minutes at 30°C in the presence of 20 µM ATP and 500 ng of recombinant MEK1 (Santa Cruz) in 40 µl of kinase buffer. MEK1 phosphorylation at Ser217/221 was determined by WB. Ras activation was determined using Ras activation assay (Upstate Biotechnology). Briefly, active Ras was purified from cell lysates using the GST fusion protein containing the Ras-binding domain of Raf-1, and detected by WB.
RT-PCR and real-time RT-PCR
Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA) including DNase I treatment. cDNA was synthesized from 2 µg of total RNA. Real-time RT-PCR conditions are described in detail elsewhere (Krejci et al., 2004). The authenticity of real-time RT-PCR products was verified by agarose electrophoresis. Table 1 lists the PCR primers used.
|
Extracellular matrix studies
For Alcian blue staining, cells were treated with CNP and pCPT-cGMP for 30 minutes prior to FGF2 treatment for 72 hours, fixed with 4% paraformaldehyde and stained with Alcian blue for 30 minutes. For MMP activity, cells were stimulated with FGF2 and CNP for 48 hours in media containing 10% FBS followed by 24 hours of cultivation in serum-free media. Conditioned culture media was normalized to cell number, concentrated ten times and subjected to non-reducing SDS-PAGE using gels containing either 1 mg/ml gelatin (Sigma) or casein (Bio-Rad, Hercules, CA). Resolved proteins were renatured by 2.5% Triton X-100 and incubated in activation buffer (50 mM Tris-HCl pH 7.5, 10 mM CaCl2) for 19 hours (gelatin) or 96 hours (casein) at 37°C. Gels were stained with Coomassie Brilliant Blue R250 (Bio-Rad). MMP activity was confirmed by incubation of gels in activation buffer containing either the MMP inhibitor EDTA (30 mM) or the serine protease inhibitor PMSF (2 mM). For evaluation of matrix synthesis, cells were treated with FGF2 and CNP for 48 or 72 hours in presence of 10 µCi/ml of [35S]sulfate or 5 µCi/ml of [3H]proline (Perkin Elmer, Boston, MA). For pulse-chase experiments, cells were labeled with [35S]sulfate or [3H]proline for 12 hours, washed and treated with FGF2 and CNP for 48 or 72 hours. Following the cultivation period, cells were harvested and incorporated radioactivity was determined by liquid scintillation. For evaluation of extracellular matrix mass, cells were treated with CNP for 48 hours, scraped or detached by Trypsin-EDTA (Gibco; 10 minutes, 37°C) and both the wet and dry mass of the cell pellets were determined.
Mass spectrometry
The protein band was excised from the acrylamide gel and subjected to tandem mass spectrometric analysis after in-gel trypsin digestion. Recovered peptides were analyzed by nanobore LC (Vydac C8 MS 0.3 mm x 15 cm; Vydac, Hesperia, CA) with electrospray sample introduction into an ion-trap mass spectrometer (Thermo Finnigan LCQ Deca XP; Thermo, San Jose, CA). To identify peptides, the tandem spectra were analyzed by searching against a National Center for Biotechnology Information-derived database.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Duration of the cGMP response in CNP-treated RCS cells
Having found that CNP inhibits FGF2-mediated long-term Erk activation only partially, we determined the time duration of the CNP signal. CNP treatment led to rapid accumulation of intracellular cGMP followed by a slow decline and stabilization from two to 12 hours (Fig. 3A). This decline was not due to the lack of CNP stability since treatment of naïve cells with CNP-containing media used previously for five hours accumulated cGMP similar to fresh CNP (not shown). Addition of fresh CNP to cells chronically treated with CNP failed to elevate cGMP levels (Fig. 3B). The protein quantities of the CNP cognate receptor, NPR-B, and the clearance receptor, NPR-C (Suga et al., 1992), were unaffected by prolonged CNP treatment (not shown) suggesting that NPR-B desensitization accounts for the decline in cGMP levels in cells chronically treated with CNP.
|
CNP inhibition of FGF2-mediated Erk activation is dependent on protein kinase G (PKG)
Cyclic GMP signals through activation of PKG, cGMP-gated ion channels (CGI) or cGMP-regulated PDE (Lucas et al., 2000). Chemical inhibition of PKG by specific inhibitor KT5823 (Kase et al., 1987
) fully restored FGF2-mediated Erk activation in the presence of CNP (Fig. 4A). Of the synthetic cGMP analogs, only pCPT-cGMP (activator of PKG and CGI but not of PDE) antagonized FGF2 growth arrest in contrast to both Rp-8-pCPT-cGMPS (inhibitor of PKG and activator of CGI with no effect on PDE) and Rp-8-Br-PET-cGMPS (inhibitor of PKG and CGI and stimulator of PDE) (Sirotkin et al., 2000
) that had no effect even at 500 µM (Fig. 4B).
|
|
Kinase active FGFRs recruit the majority of their downstream signaling pathways via tyrosine phosphorylation of the docking protein FRS2 (Kouhara et al., 1997). Immunoprecipitation of FRS2 followed by WB with the 4G10 phosphotyrosine antibody showed increased signal upon FGF2 treatment that was not decreased by CNP (Fig. 6A). However, the prominent FRS2 band showed
20 kDa upstream mobility shift in FGF2-treated cells that was reduced in FGF2/CNP-treated cells (Fig. 6A). Inhibition of FGF2-mediated Erk activation by the MEK inhibitor U0126 also eliminated the FRS2 mobility shift suggesting that Erk phosphorylates FRS2 (Fig. 6B). Interestingly, cells treated with CNP alone also showed a small but distinct FRS2 mobility shift that could be abolished by the PKG-specific inhibitor KT5823 (Fig. 6B,C).
|
CNP counteracts the FGF2-mediated loss of RCS extracellular matrix
In thanatophoric dysplasia, an increased cell to matrix ratio can be observed in the growth plate cartilage, suggesting decreased matrix production (W.R.W., unpublished). Similarly, the mouse model of achondroplasia has decreased matrix synthesis that is increased by CNP or Erk inhibition (Yasoda et al., 2004). Treatment of RCS cells with FGF2 also results in a loss of their extracellular matrix (Krejci et al., 2004
) suggesting that, apart from inhibition of proliferation, FGF signaling affects the homeostasis of chondrocyte extracellular matrix. We used the RCS model to discover how CNP and FGF signaling affect the extracellular matrix.
Cells were treated with FGF2 and CNP for 72 hours and the amount of extracellular matrix was assessed by Alcian blue staining. The loss of Alcian blue staining in FGF2-treated cells was restored by CNP (Fig. 7A) or pCPT-cGMP (not shown). During FGF2 treatment, a protein with molecular mass of approximately 300 kDa was abundantly released into the media by RCS cells. Using protein mass spectrometry, we identified this protein as fibronectin (Fig. 7B). Quantification of fibronectin mRNA by real-time RT-PCR revealed its potent upregulation by FGF2, which was significantly reversed by CNP (Fig. 7C).
|
We next investigated the mechanism of the FGF2-mediated matrix loss and its inhibition by CNP. We hypothesized that FGF2 triggers the degradation of the RCS extracellular matrix. Therefore, we asked whether FGF2 elevates expression and activity of molecules known to degrade the matrix. As determined by RT-PCR, 4 hours of treatment with FGF2 increased the quantity of matrix metalloproteinase 3 (Mmp3), Mmp10, Mmp13 and a disintegrin-like and metalloproteinase with thrombospondin motif 1 (Adamts1) and Adamts5 transcripts (Fig. 8A). The quantities of Mmp8, Mmp11 and Adamts4 transcripts were unchanged, and transcripts of Mmp7, Mmp12 and Mmp14 were not detected (not shown). The Mmp2 and Mmp9 mRNAs were also upregulated by FGF2 but this induction required at least 24 hours of treatment. We next used real-time RT-PCR to determine whether CNP interferes with the FGF2-mediated induction of these matrix-remodeling molecules. The MEK inhibitor U0126 was used to inhibit FGF2-mediated Erk activation completely. FGF2-mediated accumulation of Mmp3, Mmp10 and Mmp13 mRNAs was only weakly antagonized by CNP but was abolished by U0126 indicating the involvement of the Erk pathway. By contrast, induction of Adamts1 was only partially sensitive to CNP and U0126; Adamts5 induction was insensitive to both (Fig. 8B).
|
The moderate inhibition of both FGF2-mediated induction and activation of matrix-remodeling molecules by CNP (Fig. 8) is unlikely to fully account for the rather significant effect of CNP on FGF2-mediated matrix loss (Fig. 7). Therefore, to gain a better insight into the regulation of RCS extracellular matrix turnover, we treated cells with FGF2 and CNP for 48 or 72 hours and assessed the rate of matrix production and degradation by radioactive labeling both the sulfated proteoglycan and collagen compartments of the matrix. The [35S]sulfate uptake was significantly inhibited by FGF2 (Fig. 9A) similar to the results obtained in pulse-chase experiment (Fig. 9B) suggesting that FGF2 inhibits synthesis and triggers degradation of the proteoglycan matrix. Addition of CNP partially reversed the effects of FGF2 on the proteoglycan matrix (Fig. 9A,B). Moreover, CNP alone significantly increased [35S]sulfate incorporation (Fig. 9A). Although CNP increased both wet and dry weight of the cell pellet obtained by scraping, no effect was observed when cells were harvested by trypsinization (Fig. 9E), confirming that CNP increases the mass of the RCS extracellular matrix. FGF2 did not affect [3H]proline uptake (Fig. 9C). After 48 hours of treatment, FGF2 weakly decreased the amount of incorporated [3H]proline in one of five replicate pulse-chase experiments (not shown) in contrast to a 72 hour treatment leading to an invariant 30% loss of [3H]proline incorporation in all three replicate experiments (Fig. 9D).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Interaction of FGF and CNP signaling in the regulation of chondrocyte proliferation
In the FGFR3-related dwarfisms, the proliferating cartilage is significantly shortened and cell cycle inhibitors, such as ink4 proteins and p21Waf1, are upregulated (Li et al., 1999; Legeai-Mallet et al., 2004
). These observations have been experimentally confirmed in CFK2 and RCS chondrocyte models (Henderson et al., 2000
; Aikawa et al., 2001
), showing that inhibition of chondrocyte proliferation is a major outcome of FGF signaling in cartilage. Prolonged Erk MAP kinase activity appears to be necessary for this growth arrest to take place (Raucci et al., 2004
; Krejci et al., 2004
).
CNP can effectively prevent both Erk activation and growth arrest induced by FGF2 in RCS cells (Figs 1, 2). The CNP-mediated abolition of Erk activation depends on PKG since it is sensitive to PKG inhibition and can be mimicked by a PKG activating cGMP analog but not by PKG-inhibiting cGMP analogs (Figs 1, 2, 4). Since CNP only partially prevented FGF2-mediated growth arrest (Fig. 1), we investigated the mechanisms that limit CNP signaling in the RCS system. The duration of the CNP signal can be restricted by limited stability or clearance of CNP, desensitization of the NPR-B receptor, and PDE-mediated degradation of cGMP (Dousa et al., 1999; Silberbach and Roberts, 2001). In RCS cells, cGMP accumulation was rapidly downregulated by decreased NPR-B activity and PDE-mediated hydrolysis (Fig. 3). Although they increased steady state cGMP levels (Fig. 3C), PDE inhibitors failed to augment CNP's influence on FGF2-induced growth arrest (not shown). In addition, FGF2-induced growth arrest and long-term Erk activation was only partially prevented by PDE-resistant pCPT-cGMP (Fig. 1, Fig. 4B). We thus conclude that CNP's potential to antagonize FGF signaling is limited, and the limiting factor(s) lie downstream of cGMP. Additional experiments are ongoing to identify such factors in RCS cells.
Molecular mechanisms of FGF and CNP signaling interaction in chondrocytes
In RCS cells, FGF2-mediated activation of MEK and Raf-1 was abolished by CNP whereas activation of Ras and tyrosine phosphorylation of FRS2 were unaffected indicating that CNP signaling inhibits the Erk pathway downstream of Ras, i.e. at the level of Raf-1 (Fig. 5). Since the CNP effect on Erk activation required PKG activity (Fig. 4A), it is very likely that Raf-1 was inhibited by PKG. Interestingly, PKG is able to phosphorylate Raf-1 at Ser43, resulting in the uncoupling of the Ras/Raf-1 interaction and inactivation of the Erk pathway (Suhasini et al., 1998).
FGF-receptors recruit the Erk MAP kinase module via the membrane-anchored adaptor protein FRS2 (Kouhara et al., 1997). Kinase-active FGFRs phosphorylate FRS2 on multiple tyrosines, creating binding sites for Grb2 and Shp-2 proteins that relay the signal to the Erk pathway. Erk, in turn, limits the duration of its own activity by phosphorylating FRS2 on several threonine residues resulting in reduction of its tyrosine phosphorylation, diminished recruitment of Grb2, and ultimately downregulation of Ras/Erk activity (Lax et al., 2002
). In FGF2-treated RCS cells, FRS2 appears to be phosphorylated by Erk without diminishing the duration of Erk signal, which lasts at least 24 hours (Fig. 6B) (Krejci et al., 2004
). One likely explanation for this phenomenon is the presence of both FRS2
and FRS2ß isoforms in RCS cells, as determined by RT-PCR (not shown). Although FRS2
contains eight Erk phosphorylation sites, FRS2ß does not, being insensitive to Erk-mediated inhibition (Lax et al., 2002
). Sustained Erk activity underlies FGF-mediated growth arrest in chondrocytes in contrast to most cells where Erk is transiently activated by FGFs leading to a mitogenic outcome (Raucci et al., 2004
; Krejci et al., 2004
; Pages et al., 1993
). Thus, the ability of chondrocytes to evade negative feedback by Erk may be critical for maintenance of sustained Erk activity resulting in the unique cellular interpretation of the FGF stimulus in cartilage.
We also identified a mobility shift in FRS2 induced by CNP in a PKG-dependent manner suggesting that PKG phosphorylates FRS2 (Fig. 6B,C). There is one canonical PKG phosphorylation site (RRXS motif) in both rat FRS2 (amino acids 425-428) and FRS2ß (amino acids 178-181). It is, however, unlikely that PKG-mediated phosphorylation of FRS2 contributed to the CNP-mediated inhibition of the Erk pathway since both FGF2-mediated tyrosine phosphorylation of FRS2 and activation of Ras were unaffected by CNP (Figs 5, 6).
Interaction of FGF and CNP signaling in extracellular matrix homeostasis
The cartilaginous matrix consists predominantly of sulfated proteoglycans, as well as type II and other collagens. Evidence is emerging that the production of the chondrocyte extracellular matrix is modulated by FGF signaling. First, the growth plate cartilage of individuals suffering from thanatophoric dysplasia or murine model to achondroplasia shows an increased cell to matrix ratio, suggesting decreased matrix production (W.R.W., unpublished) (Yasoda et al., 2004). Second, the treatment of RCS chondrocytes with FGF2 results in a loss of their extracellular matrix (Krejci et al., 2004
).
We show that FGF2-mediated loss of the RCS extracellular matrix (Fig. 7) is primarily due to a reduction in its sulfated proteoglycan content (Fig. 9). Although FGF2 triggers degradation of the proteoglycan matrix (Fig. 9B), we can not clearly conclude that it inhibits proteoglycan matrix synthesis since the concomitant degradation may partially account for the decreased [35S]sulfate uptake (Fig. 9A). In an attempt to identify the molecules involved in FGF2-mediated degradation of RCS matrix, we found that FGF2 upregulated expression, release, and activation of several matrix metalloproteinases including MMP2, 3, 9, 10 and 13 (Fig. 8). Although the contribution of individual MMPs to matrix degradation was not determined here, all of the induced MMPs are capable of degrading cartilage proteoglycans (Fosang et al., 1991; Fosang et al., 1992
; Little et al., 2002
; Stickens et al., 2004
).
The significant CNP reversal of RCS extracellular matrix loss, triggered by FGF2 (Fig. 7A), appears to originate from both CNP-mediated inhibition of MMP induction (Fig. 8) and CNP stimulation of extracellular matrix synthesis (Fig. 9). It is unclear how CNP achieves the latter effect. RCS cells do not express FGF1-13 (P.K. and W.R.W., unpublished) and show rapid basal growth in contrast to potent growth arrest when exposed to minute amount of FGFs (Krejci et al., 2004). Moreover, CNP increased RCS matrix production without an increase in their proliferation as expected when antagonizing FGF signaling (Figs 1, 9). We thus conclude that CNP does not increase the amount of the RCS extracellular matrix through the interference with endogenous FGF signaling. In RCS cells, CNP elevated [35S]sulfate incorporation in an amount roughly proportional to the increase in extracellular matrix mass (Fig. 9A,E) suggesting that it upregulates proteoglycan production. However, the transcription of a panel of proteoglycans tested here was not altered by CNP thus leaving the mechanism of CNP-mediated increase in the RCS extracellular matrix open to future investigation.
Upon FGF2 treatment, we found elevated expression and release of fibronectin into the culture media (Fig. 7B,C). We presently do not know the effect of increased fibronectin on RCS cells. Addition of fibronectin to hepatic stellate or lung carcinoma cells results in Erk activation (Poulos et al., 1997; Han et al., 2005
) and thus FGF2-induced fibronectin may contribute to the maintenance of long-term Erk activity in RCS cells and thereby to FGF2-mediated growth arrest. Additional experiments are now ongoing to test this hypothesis.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aikawa, T., Segre, G. V. and Lee, K. (2001). Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J. Biol. Chem. 276, 29347-29352.
Bartels, C. F., Bükülmez, H., Padayatti, P., Rhee, D. K., van Ravenswaaij-Arts, C., Pauli, R. M., Mundlos, S., Chitayat, D., Shih, L. Y., Al-Gazali, L. I. et al. (2004). Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am. J. Hum. Genet. 75, 27-34.[CrossRef][Medline]
Chusho, H., Tamura, N., Ogawa, Y., Yasoda, A., Suda, M., Miyazawa, T., Nakamura, K., Nakao, K., Kurihara, T., Komatsu, Y. et al. (2001). Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc. Natl. Acad. Sci. USA 98, 4016-4021.
Dhillon, A. S. and Kolch, W. (2002). Untying the regulation of the Raf-1 kinase. Arch. Biochem. Biophys. 404, 3-9.[CrossRef][Medline]
Dousa, T. P. (1999). Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 55, 29-62.[CrossRef][Medline]
Drewett, J. G. and Garbers, D. L. (1994). The family of guanylyl cyclase receptors and their ligands. Endocr. Rev. 15, 135-162.[CrossRef][Medline]
Fosang, A. J., Neame, P. J., Hardingham, T. E., Murphy, G. and Hamilton, J. A. (1991). Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J. Biol. Chem. 266, 15579-15582.
Fosang, A. J., Neame, P. J., Last, K., Hardingham, T. E., Murphy, G. and Hamilton, J. A. (1992). The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J. Biol. Chem. 267, 19470-19474.
Hagiwara, H., Sakaguchi, H., Itakura, M., Yoshimoto, T., Furuya, M., Tanaka, S. and Hirose, S. (1994). Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J. Biol. Chem. 269, 10729-10733.
Han, S., Sidell, N. and Roman, J. (2005). Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett. 219, 71-81.[CrossRef][Medline]
Henderson, J. E., Naski, M. C., Aarts, M. M., Wang, D., Cheng, L., Goltzman, D. and Ornitz, D. M. (2000). Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. J. Bone Miner. Res. 15, 155-165.[Medline]
Kase, H., Iwahashi, K., Nakanishi, S., Matsuda, Y., Yamada, K., Takahashi, M., Murakata, C., Sato, A. and Kaneko, M. (1987). K-252 compounds novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 142, 436-440.[CrossRef][Medline]
Koller, K. J. and Goeddel, D. V. (1992). Molecular biology of the natriuretic peptides and their receptors. Circulation 86, 1081-1088.
Kouhara, H., Hadari, Y. R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I. and Schlessinger, J. (1997). A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89, 693-702.[CrossRef][Medline]
Krejci, P., Bryja, V., Pachernik, J., Hampl, A., Pogue, R., Mekikian, P. and Wilcox, W. R. (2004). FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp. Cell Res. 297, 152-164.[CrossRef][Medline]
Lax, I., Wong, A., Lamothe, B., Lee, A., Frost, A., Hawes, J. and Schlessinger, J. (2002). The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol. Cell 10, 709-719.[CrossRef][Medline]
Legeai-Mallet, L., Benoist-Lasselin, C., Munnich, A. and Bonaventure, J. (2004). Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 34, 26-36.[CrossRef][Medline]
Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X. Y. and Deng, C. X. (1999). A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8, 35-44.
Little, C. B., Hughes, C. E., Curtis, C. L., Janusz, M. J., Bohne, R., Wang-Weigand, S., Taiwo, Y. O., Mitchell, P. G., Otterness, I. G., Flannery, C. R. et al. (2002). Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 21, 271-288.[CrossRef][Medline]
Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K. P. and Waldman, S. A. (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-414.
Marshak, D. R., Lukas, T. J. and Watterson, D. M. (1985). Drug-protein interactions: binding of chlorpromazine to calmodulin, calmodulin fragments, and related calcium binding proteins. Biochemistry 24, 144-150.[CrossRef][Medline]
Mericq, V., Uyeda, J. A., Barnes, K. M., De Luca, F. and Baron, J. (2000). Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP. Pediatr. Res. 47, 189-193.
Miller, J. P., Boswell, K. H., Muneyama, K., Simon, L. N., Robins, R. K. and Shuman, D. A. (1973). Synthesis and biochemical studies of various 8-substituted derivatives of guanosine 3',5'-cyclic phosphate, inosine 3',5'-cyclic phosphate, and xanthosine 3',5'-cyclic phosphate. Biochemistry 12, 5310-5319.[CrossRef][Medline]
Miyazawa, T., Ogawa, Y., Chusho, H., Yasoda, A., Tamura, N., Komatsu, Y., Pfeifer, A., Hofmann, F. and Nakao, K. (2002). Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 143, 3604-3610.
Mukoyama, M., Nakao, K., Hosoda, K., Suga, S., Saito, Y., Ogawa, Y., Shirakami, G., Jougasaki, M., Obata, K., Yasue, H. et al. (1991). Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 87, 1402-1412.[Medline]
Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D. and de Crombrugghe, B. (2004). Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev. 18, 290-305.
Nakamura, H., Fujii, Y., Ohuchi, E., Yamamoto, E. and Okada, Y. (1998). Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur. J. Biochem. 253, 67-75.[CrossRef][Medline]
Okada, A., Tomasetto, C., Lutz, Y., Bellocq, J. P., Rio, M. C. and Basset, P. (1997). Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J. Cell Biol., 137, 67-77.
Pages, G., Lenormand, P., L'Allemain, G., Chambard, J. C., Meloche, S., Pouyssegur, J. (1993). Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA 90, 8319-8323.
Passos-Bueno, M. R., Wilcox, W. R., Jabs, E. W., Sertie, A. L., Alonso, L. G. and Kitoh, H. (1999). Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 14, 115-125.[CrossRef][Medline]
Poulos, J. E., Weber, J. D., Bellezzo, J. M., Di Bisceglie, A. M., Britton, R. S., Bacon, B. R. and Baldassare, J. J. (1997). Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. Am. J. Physiol. 273, G804-G811.[Medline]
Raucci, A., Laplantine, E., Mansukhani, A. and Basilico, C. (2004). Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem. 279, 1747-1756.
Rosenzweig, A. and Seidman, C. (1991). Atrial natriuretic factor and related peptide hormones. Annu. Rev. Biochem. 60, 229-255.[CrossRef][Medline]
Silberbach, M. and Roberts, C. T., Jr (2001). Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal. 13, 221-231.[CrossRef][Medline]
Sirotkin, A. V., Makarevich, A. V., Genieser, H. G., Kotwica, J., Hetenyi, L. (2000). Effect of four cGMP analogues with different mechanisms of action on hormone release by porcine ovarian granulosa cells in vitro. Exp. Clin. Endocrinol. Diabetes 108, 214-219.[CrossRef][Medline]
Stickens, D., Behonick, D. J., Ortega, N., Heyer, B., Hartenstein, B., Yu, Y., Fosang, A. J., Schorpp-Kistner, M., Angel, P. and Werb, Z. (2004). Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 131, 5883-5895.
Suga, S., Nakao, K., Hosoda, K., Mukoyama, M., Ogawa, Y., Shirakami, G., Arai, H., Kambayashi, Y., Inouye, K. et al. (1992). Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 130, 229-239.[Abstract]
Suhasini, M., Li, H., Lohmann, S. M., Boss, G. R. and Pilz, R. B. (1998). Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol. Cell. Biol. 18, 6983-6994.
Takase, Y., Saeki, T., Watanabe, N., Adachi, H., Souda, S. and Saito, I. (1994). Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J. Med. Chem. 37, 2106-2111.[CrossRef][Medline]
Tamura, N., Doolittle, L. K., Hammer, R. E., Shelton, J. M., Richardson, J. A. and Garbers, D. L. (2004). Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc. Natl. Acad. Sci. USA 101, 17300-17305.
Tsuji, T. and Kunieda, T. (2005). A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J. Biol. Chem. 280, 14288-14292.
Wilcox, W. R., Tavormina, P. L., Krakow, D., Kitoh, H., Lachman, R. S., Wasmuth, J. J., Thompson, L. M. and Rimoin, D. L. (1998). Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am. J. Med. Genet. 78, 274-281.[CrossRef][Medline]
Yasoda, A., Ogawa, Y., Suda, M., Tamura, N., Mori, K., Sakuma, Y., Chusho, H., Shiota, K., Tanaka, K. and Nakao, K. (1998). Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J. Biol. Chem. 273, 11695-11700.
Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T., Rogi, T., Tanaka, S., Suda, M. et al. (2004). Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat. Med. 10, 80-86.[CrossRef][Medline]
|